Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aligos and Xiamen Amoytop sign deal for HBV therapy
This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by
This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by
The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna’s MNM technology as a delivery enhancer for therapeutic modalities. Interna’s MNM molecules
The collaboration aims to bridge gaps between data generation and actionable insights in spatial proteomics, as multiplex technologies for imaging advance. Spatial proteomics platforms create intricate tissue data,
This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim’s DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with
The financing will support Adcendo’s ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of three main
The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. The therapy is anticipated to have a US Food and Drug Administration
The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition. FSGS is
The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. The FDA has scheduled a decision date for 10 October 2026
According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets. C4 Therapeutics will use its TORPEDO platform for
Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan & Lee. Under the agreement, JW Pharmaceutical gains exclusive rights to develop and commercialise the